Understanding how Mounjaro works systemically is important when considering its potential effects on other bodily functions, including the menstrual cycle
Currently available incretin-based therapies include GLP-1 receptor agonists such as semaglutide (Ozempic for diabetes
Tirzepatide, the active ingredient in Mounjaro, is a dual GLP-1 and GIP receptor agonist now widely used for weight loss and blood sugar control
It provides the support needed to navigate daily challenges without overwhelming the system
To follow up on that study, the investigators wanted to explore the weight-loss effects of the broader class of GLP-1 receptor agonists, including agents that targeted one or two additional pathways, in individuals without diabetes
They can help patients improve and protect their health, so its worth having a conversation with your provider if you think you could benefit